NanoString Technologies said Monday it expects Q2 revenue of over $44 million, about a 37% increase from a year earlier and above its guidance of $40 million to $42 million.
Analysts polled by.
SEATTLE - NanoString Technologies, Inc. , a leading provider of life science tools for discovery and translational research, today announced, as required by Nasdaq Stock Market Rules, equity.
Cutting-edge spatial omics technologies to map cancer cells and their immune environment in high resolution, allowing AI to unlock potential for new breakthrough treatments Landmark research project
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that the Company will host a conference call on Monday
NanoString Technologies, Inc. (Nasdaq: NSTG), a leading provider of life science tools for discovery and translational research, today responded to the Regional Court of Munich's recent decision finding